NICE guidance on bortezomib for induction treatment in myeloma before high-dose chemotherapy and autologous stem cell transplantation

Bortezomib is recommended as induction treatment in combination with dexamethasone, or with dexamethasone and thalidomide, for previously untreated myeloma patients who are eligible for high-dose chemotherapy and haematopoietic stem cell transplantation.